The Hedgehog signaling pathway - Implications for drug targets in cancer and neurodegenerative disorders

Pharmacogenomics

Volumn 4, Issue 4, 2003, Pages 411-429

  Bak, Mads ^a   Hansen, Claus ^a   Tommerup, Niels ^a   Larsen, Lars Allan ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; Cyclopamine; Development; Diabetic neuropathy; Hedgehog signaling pathway; Neurodegenerative disorders; Parkinson's disease; Stem cells

Indexed keywords

CYCLOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN G; LEVODOPA; NEUROTROPHIC FACTOR; POLYPEPTIDE; PROTEIN INHIBITOR; RECOMBINANT PROTEIN; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL TYPE; CENTRAL NERVOUS SYSTEM; CONGENITAL DISORDER; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG ISOLATION; DRUG TARGETING; DYSKINESIA; EMBRYO PATTERN FORMATION; GENE MUTATION; GENETIC CONSERVATION; HUMAN; MOLECULAR INTERACTION; NERVE CELL; NEURAL TUBE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN MODIFICATION; PSYCHOSIS; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DELIVERY SYSTEMS; HEDGEHOG PROTEINS; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

ERINACEIDAE;

EID: 0037769109     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.4.4.411.22751     Document Type: Review

References (176)

1. Nüsslein-Volhard C, Wieschaus E: Mutations affecting segment number and polarity in Drosophila. Nature 287, 795-801 (1980).
2. Tabata T, Eaton S, Kornberg TB: The Drosophila Hedgehog gene is expressed specifically in posterior compartment cells and is a target of engrailed regulation. Genes Dev. 6, 2635-2645 (1992).
3. Tashiro S, Michiue T, Higashijima S et al.: Structure and expression of Hedgehog, a Drosophila segment-polarity gene required for cell-cell communication. Gene 124, 183-189 (1993).
4. Lee JJ, von Kessler DP, Parks S et al.: Secretion and localized transcription suggest a role in positional signaling for products of the segmentation gene Hedgehog. Cell 71, 33-50 (1992).
5. Mohler J, Vani K: Molecular organization and embryonic expression of the Hedgehog gene involved in cell-cell communication in segmental patterning of Drosophila. Development 115, 957-971 (1992).
6. Bumcrot DA, Takada R, McMahon AP: Proteolytic processing yields two secreted forms of sonic Hedgehog. Mol. Cell Biol. 15, 2294-2303 (1995).
7. Lee JJ, Ekker SC, von Kessler DP et al.: Autoproteolysis in Hedgehog protein biogenesis. Science 266, 1528-1537 (1994).
8. Porter JA, Young KE, Beachy PA: Cholesterol modification of Hedgehog signaling proteins in animal development. Science 274, 255-259 (1996).
9. Pepinsky RB, Zeng C, Wen D et al.: Identification of a palmitic acid-modified form of human Sonic Hedgehog. J. Biol. Chem. 273, 14037-14045 (1998).
10. Burke R, Nellen D, Bellotto M et al.: Dispatched, a novel sterol-sensing domain protein dedicated to the release of cholesterol-modified Hedgehog from signaling cells. Cell 99, 803-815 (1999).
11. Briscoe J, Chen Y, Jessell TM et al.: A Hedgehog-insensitive form of patched provides evidence for direct long-range morphogen activity of sonic Hedgehog in the neural tube. Mol. Cell 7, 1279-1291 (2001).
12. Hynes M, Ye W, Wang K et al.: The seven-transmembrane receptor smoothened cell-autonomously induces multiple ventral cell types. Nat. Neurosci. 3, 41-46 (2000).
13. Wijgerde M, McMahon JA, Rule M et al.: A direct requirement for Hedgehog signaling for normal specification of all ventral progenitor domains in the presumptive mammalian spinal cord. Genes Dev. 16, 2849-2864 (2002).
14. Briscoe J, Ericson J: Specification of neuronal fates in the ventral neural tube. Curr. Opin. Neurobiol. 11, 43-49 (2001).
15. Niswander L: Pattern formation: old models out on a limb. Nat. Rev. Genet. 4, 133-143 (2003).
16. Caspary T, Garcia-Garcia MJ, Huangfu D et al.: Mouse Dispatched homolog1 is required for long-range but not juxtacrine, Hh signaling. Curr. Biol. 12, 1628-1632 (2002).
17. Ma Y, Erkner A, Gong R et al.: Hedgehog-mediated patterning of the mammalian embryo requires transporter-like function of dispatched. Cell 111, 63-75 (2002).
18. Kawakami T, Kawcak T, Li YJ et al.: Mouse dispatched mutants fail to distribute Hedgehog proteins and are defective in Hedgehog signaling. Development 129, 5753-5765 (2002).
19. Kuwabara PE, Labouesse M: The sterol-sensing domain: multiple families, a unique role? Trends Genet. 18, 193-201 (2002).
20. Bellaiche Y, The I, Perrimon N: Tout-velu is a Drosophila homologue of the putative tumor suppressor EXT-1 and is needed for Hh diffusion. Nature 394, 85-88 (1998).
21. The I, Bellaiche Y, Perrimon N: Hedgehog movement is regulated through tout velu-dependent synthesis of a heparan sulfate proteoglycan. Mol. Cell 4, 633-639 (1999).
22. Rubin JB, Choi Y, Segal RA: Cerebellar proteoglycans regulate sonic Hedgehog responses during development. Development 129, 2223-2232 (2002).
23. Stone DM, Hynes M, Armanini M et al.: The tumor-suppressor gene patched encodes a candidate receptor for Sonic Hedgehog. Nature 384, 129-134 (1996).
24. Murone M, Rosenthal A, de Sauvage FJ: Sonic Hedgehog signaling by the patched-smoothened receptor complex. Curr. Biol. 9, 76-84 (1999).
25. Incardona JP, Gruenberg J, Roelink H: Sonic Hedgehog induces the segregation of patched and smoothened in endosomes. Curr. Biol. 12, 983-995 (2002).
26. Johnson RL, Milenkovic L, Scott MP: In vivo functions of the patched protein: requirement of the C terminus for target gene inactivation but not Hedgehog sequestration. Mol. Cell 6, 467-478 (2000).
27. Taipale J, Cooper MK, Maiti T et al.: Patched acts catalytically to suppress the activity of Smoothened. Nature 418, 892-897 (2002).
28. Ingham PW, Nystedt S, Nakano Y et al.: Patched represses the Hedgehog signaling pathway by promoting modification of the Smoothened protein. Curr. Biol. 10, 1315-1318 (2000).
29. Denef N, Neubuser D, Perez L et al.: Hedgehog induces opposite changes in turnover and subcellular localization of patched and smoothened. Cell 102, 521-531 (2000).
30. Alcedo J, Zou Y, Noll M Post-transcriptional regulation of smoothened is part of a self-correcting mechanism in the Hedgehog signaling system. Mol. Cell 6, 457-465 (2000).
31. Zhu AJ, Zheng L, Suyama K et al.: Altered localization of Drosophila Smoothened protein activates Hedgehog signal transduction. Genes Dev. 17, 1240-1252 (2003).
32. Eggenschwiler JT, Espinoza E, Anderson KV: Rab23 is an essential negative regulator of the mouse Sonic Hedgehog signaling pathway. Nature 412, 194-198 (2001).
33. Incardona JP, Lee JH, Robertson CP et al.: Receptor-mediated endocytosis of soluble and membrane-tethered sonic Hedgehog by patched-1. Proc. Natl. Acad. Sci. USA 97, 12044-12049 (2000).
34. Karpen HE, Bukowski JT, Hughes T et al.: The sonic Hedgehog receptor patched associates with caveolin-1 in cholesterol-rich microdomains of the plasma membrane. J. Biol. Chem. 276, 19503-19511 (2001).
35. Lewis PM, Dunn MP, McMahon JA et al.: Cholesterol modification of sonic Hedgehog is required for long-range signaling activity and effective modulation of signaling by Ptc1. Cell 105, 599-612 (2001).
36. Chuang PT, McMahon AP: Vertebrate Hedgehog signaling modulated by induction of a Hedgehog-binding protein. Nature 397, 617-621 (1999).
37. Bak M, Hansen C, Friis HK et al.: The human Hedgehog-interacting protein gene: Structure and chromosome mapping to 4q31.21 - > q31.3. Cytogenet. Cell Genet. 92, 300-303 (2001).
38. Chuang PT, Kawcak T, McMahon AP: Feedback control of mammalian Hedgehog signaling by the Hedgehog-binding protein, Hip1, modulates Fgf signaling during branching morphogenesis of the lung. Genes Dev. 17, 342-347 (2003).
39. Lee CS, Buttitta L, Fan CM: Evidence that the WNT-inducible growth arrest-specific gene 1 encodes an antagonist of sonic Hedgehog signaling in the somite. Proc. Natl. Acad. Sci. USA 98, 11347-11352 (2001).
40. McCarthy RA, Barth JL, Chintalapudi MR et al.: Megalin functions as an endocytic sonic Hedgehog receptor. J. Biol. Chem. 277, 25660-25667 (2002).
41. Ingham PW and McMahon AP: Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15, 3059-3087 (2001).
42. Wang G, Wang B, Jiang J: Protein kinase A antagonizes Hedgehog signaling by regulating both the activator and repressor forms of Cubitus interruptus. Genes Dev. 13, 2828-2837 (1999).
43. Price MA and Kalderon D: Proteolysis of the Hedgehog signaling effector Cubitus interruptus requires phosphorylation by Glycogen Synthase Kinase 3 and Casein Kinase 1. Cell 108, 823-835 (2002).
44. Jia J, Amanai K, Wang G et al.: Shaggy/GSK3 antagonizes Hedgehog signaling by regulating Cubitus interruptus. Nature 416, 548-552 (2002).
45. Jiang J, Struhl G: Regulation of the Hedgehog and Wingless signaling pathways by the F-box/WD40-repeat protein Slimb. Nature 391, 493-496 (1998).
46. Methot N, Basler K: Suppressor of fused opposes Hedgehog signal transduction by impeding nuclear accumulation of the activator form of Cubitus interruptus. Development 127, 4001-4010 (2000).
47. Wang G, Amanai K, Wang B et al.: Interactions with costal2 and suppressor of fused regulate nuclear translocation and activity of cubitus interruptus. Genes Dev. 14, 2893-2905 (2000).
48. Chen CH, von Kessler DP, Park W et al.: Nuclear trafficking of Cubitus interruptus in the transcriptional regulation of Hedgehog target gene expression. Cell 98, 305-316 (1999).
49. Nybakken KE, Turck CW, Robbins DJ et al.: Hedgehog-stimulated phosphorylation of the kinesin-related protein Costal2 is mediated by the serine/threonine kinase fused. J. Biol. Chem. 277, 24638-24647 (2002).
50. Robbins DJ, Nybakken KE, Kobayashi R et al.: Hedgehog elicits signal transduction by means of a large complex containing the kinesin-related protein costal2. Cell 90, 225-234 (1997).
51. Hynes M, Stone DM, Dowd M et al.: Control of cell pattern in the neural tube by the zinc-finger transcription factor and oncogene Gli-1. Neuron 19, 15-26 (1997).
52. Sasaki H, Hui C, Nakafuku M et al.: A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. Development 124, 1313-1322 (1997).
53. Altaba A: Gli proteins encode context-dependent positive and negative functions: implications for development and disease. Development 126, 3205-3216 (1999).
54. Altaba A Combinatorial Gli gene function in floor plate and neuronal inductions by Sonic Hedgehog. Development 125, 2203-2212 (1998).
55. Marigo V, Johnson RL, Vortkamp A et al.: Sonic Hedgehog differentially regulates expression of GLI and GLI3 during limb development. Dev. Biol. 180, 273-283 (1996).
56. Lee J, Platt KA, Censullo P et al.: Gli1 is a target of Sonic Hedgehog that induces ventral neural tube development. Development 124, 2537-2552 (1997).
57. Bai CB, Auerbach W, Lee JS et al.: Gli2 but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development 129, 4753-4761 (2002).
58. Park HL, Bai C, Platt KA et al.: Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development 127, 1593-1605 (2000).
59. Mao J, Maye P, Kogerman P et al.: Regulation of Gli1 transcriptional activity in the nucleus by Dyrk1. J. Biol. Chem. 277, 35156-35161 (2002).
60. Mizugishi K, Aruga J, Nakata K et al.: Molecular properties of Zic proteins as transcriptional regulators and their relationship to GLI proteins. J. Biol. Chem. 276, 2180-2188 (2001).
61. Koyabu Y, Nakata K, Mizugishi K et al.: Physical and functional interactions between Zic and Gli proteins. J. Biol. Chem. 276, 6889-6892 (2001).
62. Dai P, Shinagawa T, Nomura T et al.: Ski is involved in transcriptional regulation by the repressor and full-length forms of Gli3. Genes Dev. 16, 2843-2848 (2002).
63. Kinzler KW and Vogelstein B The GLI gene encodes a nuclear protein which binds specific sequences in the human genome. Mol. Cell Biol. 10, 634-642 (1990).
64. Chen Y, Goodman RH, Smolik SM: Cubitus interruptus requires Drosophila CREB-binding protein to activate wingless expression in the Drosophila embryo. Mol. Cell Biol. 20, 1616-1625 (2000).
65. Akimaru H, Chen Y, Dai P et al.: Drosophila CBP is a co-activator of cubitus interruptus in Hedgehog signaling. Nature 386, 735-738 (1997).
66. Dai P, Akimaru H, Tanaka Y et al.: Sonic Hedgehog-induced activation of the Gli1 promoter is mediated by GLI3. J. Biol. Chem. 274, 8143-8152 (1999).
67. Alexandre C, Jacinto A, Ingham PW Transcriptional activation of Hedgehog target genes in Drosophila is mediated directly by the cubitus interruptus protein, a member of the GLI family of zinc-finger DNA-binding proteins. Genes Dev. 10, 2003-2013 (1996).
68. Mullor JL, Sanchez P, Altaba AR: Pathways and consequences: Hedgehog signaling in human disease. Trends Cell Biol. 12, 562-569 (2002).
69. Brown SA, Warburton D, Brown LY et al.: Holoprosencephaly due to mutations in ZIC2, a homologue of Drosophila odd-paired. Nat. Genet. 20, 180-183 (1998).
70. Belloni E, Muenke M, Roessler E et al.: Identification of Sonic Hedgehog as a candidate gene responsible for holoprosencephaly. Nat. Genet. 14, 353-356 (1996).
71. Ming JE, Kaupas ME, Roessler E et al.: Mutations in PATCHED-1, the receptor for SONIC Hedgehog, are associated with holoprosencephaly. Hum. Genet. 110, 297-301 (2002).
72. Roessler E, Belloni E, Gaudenz K et al.: Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nat. Genet. 14, 357-360 (1996).
73. Gripp KW, Wotton D, Edwards MC et al.: Mutations in TGIF cause holoprosencephaly and link NODAL signaling to human neural axis determination. Nat. Genet. 25, 205-208 (2000).
74. Sulik KK, Dehart DB, Rogers JM et al.: Teratogenicity of low doses of all-trans retinoic acid in presomite mouse embryos. Teratology 51, 398-403 (1995).
75. Helms JA, Kim CH, Hu D et al.: Sonic Hedgehog participates in craniofacial morphogenesis and is downregulated by teratogenic doses of retinoic acid. Dev. Biol. 187, 25-35 (1997).
76. Gao B, Guo J, She C et al.: Mutations in IHH, encoding Indian Hedgehog, cause brachydactyly type A- 1. Nat. Genet. 28, 386-388 (2001).
77. Hellemans J, Coucke PJ, Giedion A et al.: Homozygous Mutations in IHH Cause Acrocapitofemoral Dysplasia, an Autosomal Recessive Disorder with Cone-Shaped Epiphyses in Hands and Hips. Am. J. Hum. Genet. 72, 1040-1046 (2003).
78. Vortkamp A, Gessler M, Grzeschik KH: GLI3 zinc-finger gene interrupted by translocations in Greig syndrome families. Nature 352, 539-540 (1991).
79. Kalff-Suske M, Wild A, Topp J et al.: Point mutations throughout the GLI3 gene cause Greig cephalopolysyndactyly syndrome. Hum. Mol. Genet. 8, 1769-1777 (1999).
80. Kang S, Graham JM, Jr., Olney AH et al.: GLI3 frameshift mutations cause autosomal dominant Pallister-Hall syndrome. Nat. Genet. 15, 266-268 (1997).
81. Radhakrishna U, Wild A, Grzeschik KH et al.: Mutation in GLI3 in postaxial polydactyly type A. Nat. Genet. 17, 269-271 (1997).
82. Radhakrishna U, Bornholdt D, Scott HS et al.: The phenotypic spectrum of GLI3 morphopathies includes autosomal dominant preaxial polydactyly type-IV and postaxial polydactyly type-A/B; No phenotype prediction from the position of GLI3 mutations. Am. J. Hum. Genet. 65, 645-655 (1999).
83. Petrij F, Giles RH, Dauwerse HG et al.: Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376, 348-351 (1995).
84. Blough RI, Petrij F, Dauwerse JG et al.: Variation in microdeletions of the cyclic AMP-responsive element-binding protein gene at chromosome band 16p13.3 in the Rubinstein-Taybi syndrome. Am. J. Med. Genet. 90, 29-34 (2000).
85. Hahn H, Wicking C, Zaphiropoulous PG et al.: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841-851 (1996).
86. Johnson RL, Rothman AL, Xie J et al.: Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272, 1668-1671 (1996).
87. Evans DG, Ladusans EJ, Rimmer S et al.: Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J. Med. Genet. 30, 460-464 (1993).
88. Kimonis VE, Goldstein AM, Pastakia B et al.: Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am. J. Med. Genet. 69, 299-308 (1997).
89. Lo ML, Nocini PF, Savoia A et al.: Nevoid basal cell carcinoma syndrome. Clinical findings in 37 Italian affected individuals. Clin. Genet. 55, 34-40 (1999).
90. Smyth I, Narang MA, Evans T et al.: Isolation and characterization of human patched 2 (PTCH2), a putative tumor suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum. Mol. Genet. 8, 291-297 (1999).
91. Taylor MD, Liu L, Raffel C et al.: Mutations in SUFU predispose to medulloblastoma. Nat. Genet. 31, 306-310 (2002).
92. Bonifas JM, Pennypacker S, Chuang PT et al.: Activation of expression of Hedgehog target genes in basal cell carcinomas. J. Invest Dermatol. 116, 739-742 (2001).
93. Dahmane N, Lee J, Robins P et al.: Activation of the transcription factor Gli1 and the Sonic Hedgehog signaling pathway in skin tumors. Nature 389, 876-881 (1997).
94. Green J, Leigh IM, Poulsom R et al.: Basal cell carcinoma development is associated with induction of the expression of the transcription factor Gli-1. Br. J. Dermatol. 139, 911-915 (1998).
95. Pomeroy SL, Tamayo P, Gaasenbeek M et al.: Prediction of central nervous system embryonal tumor outcome based on gene expression. Nature 415, 436-442 (2002).
96. Dahmane N, Sanchez P, Gitton Y et al.: The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 128, 5201-5212 (2001).
97. Watkins DN, Berman DM, Burkholder SG et al.: Hedgehog signaling within airway epithelial progenitors and in small-cell lung cancer. Nature 422, 313-317 (2003).
98. Grachtchouk M, Mo R, Yu S et al.: Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat. Genet. 24, 216-217 (2000).
99. Nilsson M, Unden AB, Krause D et al.: Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc. Natl. Acad. Sci. USA 97, 3438-3443 (2000).
100. Oro AE, Higgins KM, Hu Z et al.: Basal cell carcinomas in mice overexpressing sonic Hedgehog. Science 276, 817-821 (1997).
101. Goodrich LV, Milenkovic L, Higgins KM et al.: Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 277, 1109-1113 (1997).
102. Hahn H, Wojnowski L, Zimmer AM et al.: Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat. Med. 4, 619-622 (1998).
103. Aszterbaum M, Epstein J, Oro A et al.: Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomata in patched heterozygous knockout mice. Nat. Med. 5, 1285-1291 (1999).
104. Pazzaglia S, Mancuso M, Atkinson MJ et al.: High incidence of medulloblastoma following X-ray-irradiation of newborn Ptc1 heterozygous mice. Oncogene 21, 7580-7584 (2002).
105. Sidransky D: Is human patched the gatekeeper of common skin cancers? Nat. Genet. 14, 7-8 (1996).
106. Zurawel RH, Allen C, Wechsler-Reya R et al.: Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer 28, 77-81 (2000).
107. Calzada-Wack J, Kappler R, Schnitzbauer U et al.: Unbalanced overexpression of the mutant allele in murine Patched mutants. Carcinogenesis 23, 727-733 (2002).
108. Zhang Y and Kalderon D: Hedgehog acts as a somatic stem cell factor in the Drosophila ovary. Nature 410, 599-604 (2001).
109. Lai K, Kaspar BK, Gage FH et al.: Sonic Hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat. Neurosci. 6, 21-27 (2003).
110. Altaba A, Sanchez P, Dahmane N: Gli and Hedgehog in cancer: tumors, embryos and stem cells. Nat. Rev. Cancer 2, 361-372 (2002).
111. Taipale J and Beachy PA: The Hedgehog and Wnt signaling pathways in cancer. Nature 411, 349-354 (2001).
112. Duman-Scheel M, Weng L, Xin S et al.: Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature 417, 299-304 (2002).
113. Kenney AM and Rowitch DH: Sonic Hedgehog promotes G(1) cyclin expression and sustained cell cycle progression in mammalian neuronal precursors. Mol. Cell Biol. 20, 9055-9067 (2000).
114. Zhao Q, Kho A, Kenney AM et al.: Identification of genes expressed with temporal-spatial restriction to developing cerebellar neuron precursors by a functional genomic approach. Proc. Natl. Acad. Sci. USA 99, 5704-5709 (2002).
115. Louro ID, Bailey EC, Li X et al.: Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation. Cancer Res. 62, 5867-5873 (2002).
116. Yoon JW, Kita Y, Frank DJ et al.: Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J. Biol. Chem. 277, 5548-5555 (2002).
117. Keeler RF Cyclopamine and related steroidal alkaloid teratogens: their occurrence, structural relationship and biologic effects. Lipids 13, 708-715 (1978).
118. Chiang C, Litingtung Y, Lee E et al.: Cyclopia and defective axial patterning in mice lacking Sonic Hedgehog gene function. Nature 383, 407-413 (1996).
119. Cooper MK, Porter JA, Young KE et al.: Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280, 1603-1607 (1998).
120. Incardona JP, Gaffield W, Kapur RP et al.: The teratogenic Veratrum alkaloid cyclopamine inhibits sonic Hedgehog signal transduction. Development 125, 3553-3562 (1998).
121. Chen JK, Taipale J, Cooper MK et al.: Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 16, 2743-2748 (2002).
122. Chen JK, Taipale J, Young KE et al.: Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. USA 99, 14071-14076 (2002).
123. Frank-Kamenetsky M, Zhang XM, Bottega S et al.: Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J. Biol. 1, 10 (2002).
124. King RW Roughing up Smoothened: chemical modulators of Hedgehog signaling. J. Biol. 1, 8 (2002).
125. Frank-Kamenetsky M, Zhang XM, Bottega S et al.: Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J. Biol. 1, 10 (2002).
126. Chen JK, Taipale J, Young KE et al.: Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. USA 99, 14071-14076 (2002).
127. Taipale J, Chen JK, Cooper MK, et al.: Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406, 1005-1009 (2000).
128. Taipale J, Chen JK, Cooper MK et al.: Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406, 1005-1009 (2000).
129. Berman DM, Karhadkar SS, Hallahan AR et al.: Medulloblastoma growth inhibition by Hedgehog pathway blockade. Science 297, 1559-1561 (2002).
130. Koike C, Mizutani T, Ito T et al.: Introduction of wild type patched gene suppresses the oncogenic potential of human squamous cell carcinoma cell lines including A431. Oncogene 21, 2670-2678 (2002).
131. Bonnet AM, Houeto JL: Pathophysiology of Parkinson's disease. Biomed. Pharmacother. 53, 117-121 (1999).
132. Abbas N, Lucking CB, Ricard S et al.: A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's disease. Hum. Mol. Genet. 8, 567-574 (1999).
133. Wakabayashi K, Matsumoto K, Takayama K et al.: NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett. 239, 45-48 (1997).
134. Marsden CD: Problems with long-term levodopa therapy for Parkinson's disease. Clin. Neuropharmacol. 17 Suppl. 2, S32-S44 (1994).
135. Brundin P, Pogarell O, Hagell P et al.: Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123 (Pt 7), 1380-1390 (2000).
136. Horger BA, Nishimura MC, Armanini MP et al.: Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 18, 4929-4937 (1998).
137. Milbrandt J, Fahrner TJ et al.: Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20, 245-253 (1998).
138. Rosenblad C, Grønborg M, Hansen C et al.: In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. Mol. Cell Neurosci. 15, 199-214 (2000).
139. Miao N, Wang M, Ott JA et al.: Sonic Hedgehog promotes the survival of specific CNS neuron populations and protects these cells from toxic insult In vitro. J. Neurosci. 17, 5891-5899 (1997).
140. Pepinsky RB, Shapiro RI, Wang S et al.: Long-acting forms of Sonic Hedgehog with improved pharmacokinetic and pharmacodynamic properties are efficacious in a nerve injury model. J. Pharm. Sci. 91, 371-387 (2002).
141. Tsuboi K, Shults CW: Intrastriatal injection of sonic Hedgehog reduces behavioural impairment in a rat model of Parkinson's disease. Exp. Neurol. 173, 95-104 (2002).
142. Dass B, Iravani MM, Jackson MJ et al.: Behavioural and immunohistochemical changes following supranigral administration of sonic Hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Neuroscience 114, 99-109 (2002).
143. Lie DC, Dziewczapolski G, Willhoite AR et al.: The adult substantia nigra contains progenitor cells with neurogenic potential. J. Neurosci. 22, 6639-6649 (2002).
144. Kay JN and Blum M: Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection. Dev. Neurosci. 22, 56-67 (2000).
145. Porter JA, Ekker SC, Park WJ et al.: Hedgehog patterning activity: role of a lipophilic modification mediated by the carboxy-terminal autoprocessing domain. Cell 86, 21-34 (1996).
146. Calcutt NA, Allendoerfer KL, Mizisin AP et al.: Therapeutic efficacy of sonic Hedgehog protein in experimental diabetic neuropathy. J. Clin. Invest 111, 507-514 (2003).
147. Pitre DA, Seifert JL, Bauer JA: Perineurium inflammation and altered connexin isoform expression in a rat model of diabetes related peripheral neuropathy. Neurosci. Lett. 303, 67-71 (2001).
148. Rechthand E, Smith QR, Latker CH et al.: Altered blood-nerve barrier permeability to small molecules in experimental diabetes mellitus. J. Neuropathol. Exp. Neurol. 46, 302-314 (1987).
149. Mirsky R, Parmantier E, McMahon AP et al.: Schwann cell-derived desert Hedgehog signals nerve sheath formation. Ann. NY Acad. Sci. 883, 196-202 (1999).
150. Umehara F, Tate G, Itoh K et al.: A novel mutation of desert Hedgehog in a patient with 46,XY partial gonadal dysgenesis accompanied by minifascicular neuropathy. Am. J. Hum. Genet. 67, 1302-1305 (2000).
151. Teleman AA, Strigini M, Cohen SM: Shaping morphogen gradients. Cell 105, 559-562 (2001).
152. Greco V, Hannus M, Eaton S: Argosomes: a potential vehicle for the spread of morphogens through epithelia. Cell 106, 633-645 (2001).
153. Paganelli AR, Ocana OH, Prat MI et al.: The Alzheimer-related gene presenilin-1 facilitates sonic Hedgehog expression in Xenopus primary neurogenesis. Mech. Devel. 107, 119-131 (2001).
154. Sobel RA: The extracellular matrix in multiple sclerosis: an update. Braz. J. Med. Biol. Res. 34, 603-609 (2001).
155. Wuyts W, Van Hul W: Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2 genes. Hum. Mutat. 15, 220-227 (2000).
156. Wassif CA, Maslen C, Kachilele-Linjewile S et al.: Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith-Lemli-Opitz syndrome. Am. J. Hum. Genet. 63, 55-62 (1998).
157. Waterham HR, Wijburg FA, Hennekam RC et al.: Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol reductase gene. Am. J. Hum. Genet. 63, 329-338 (1998).
158. Hahn H, Wojnowski L, Miller G et al.: The patched signaling pathway in tumorigenesis and development: lessons from animal models. J. Mol. Med. 77, 459-468 (1999).
159. Xie J, Murone M, Luoh SM et al.: Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391, 90-92 (1998).
160. Reifenberger J, Wolter M, Weber RG et al.: Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 58, 1798-1803 (1998).
161. Evans T, Boonchai W, Shanley S et al.: The spectrum of patched mutations in a collection of Australian basal cell carcinomas. Hum. Mutat. 16, 43-48 (2000).
162. Gailani MR, Stahle-Backdahl M, Leffell DJ et al.: The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat. Genet. 14, 78-81 (1996).
163. Unden AB, Holmberg E, Lundh-Rozell B et al.: Mutations in the human homologue of Drosophila patched (PTCH) in basal cell carcinomas and the Gorlin syndrome: different in vivo mechanisms of PTCH inactivation. Cancer Res. 56, 4562-4565 (1996).
164. Wolter M, Reifenberger J, Sommer C et al.: Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 57, 2581-2585 (1997).
165. Barreto DC, Gomez RS, Bale AE et al.: PTCH gene mutations in odontogenic keratocysts. J. Dent. Res. 79, 1418-1422 (2000).
166. Wetmore C, Eberhart DE, Curran T: Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res. 61, 513-516 (2001).
167. Pietsch T, Waha A, Koch A et al.: medulloblastoma of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res. 57, 2085-2088 (1997).
168. Raffel C, Jenkins RB, Frederick L et al.: Sporadic medulloblastoma contain PTCH mutations. Cancer Res. 57, 842-845 (1997).
169. Vorechovsky I, Tingby O, Hartman M et al.: Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumors. Oncogene 15, 361-366 (1997).
170. Xie J, Johnson RL, Zhang X et al.: Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res. 57, 2369-2372 (1997).
171. Ping XL, Ratner D, Zhang H et al.: PTCH mutations in squamous cell carcinoma of the skin. J. Invest Dermatol. 116, 614-616 (2001).
172. Maesawa C, Tamura G, Iwaya T et al.: Mutations in the human homologue of the Drosophila patched gene in esophageal squamous cell carcinoma. Genes Chromosomes. Cancer 21, 276-279 (1998).
173. McGarvey TW, Maruta Y, Tomaszewski JE et al.: PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene 17, 1167-1172 (1998).
174. Vorechovsky I, Unden AB, Sandstedt B et al.: Trichoepitheliomas contain somatic mutations in the overexpressed PTCH gene: support for a gatekeeper mechanism in skin tumorigenesis. Cancer Res. 57, 4677-4681 (1997).
175. Chang-Claude J, Dunning A, Schnitzbauer U et al.: The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk. Int. J. Cancer 103, 779-783 (2003).
176. Vorechovsky I, Benediktsson KP, Toftgard R: The patched/Hedgehog/smoothened signaling pathway in human breast cancer: no evidence for H133Y SHH, PTCH and SMO mutations. Eur. J. Cancer 35, 711-713 (1999).